Bevacizumab and VEGF165 conditional QSS binding

5 mg/kg every 2 weeks, 70 kg,85-minute fixed infusions

Specified deterministic infusion and fixed-covariate history.

Readouts

Total bevacizumab · Unit unavailable

Specified fixed-context quantity, unit coordinate or accounting readout.

Free VEGF165 · ng/L

Free serum VEGF165 model readout.

Accounted bevacizumab · mg

Specified fixed-context quantity, unit coordinate or accounting readout.

Accounted target · nmol

Specified fixed-context quantity, unit coordinate or accounting readout.

Study purpose

• How do the model's key biological readouts change under 5 mg/kg every 2 weeks, 70 kg,85-minute fixed infusions?

Assumptions

• Deterministic fixed histories only; no original individual fitting, sampled populations or clinical dose selection.
• Body weight and allometric coefficients stay fixed. Clearances scale with weight exponent0.75 and volumes with exponent1 relative to70kg.
• Infusion durations are explicit chosen histories, not recovered individual infusion records.
• All accounting and elapsed-time states are nonfeedback observers. AUC keeps physical mg*day/L under alternate hour display.
• No claim of published figure-panel, population, residual-error or genotype-effect reconstruction.
• Free central drug, free target and effective1:1complex are algebraic QSS quantities, not kon/koff kinetic states.
• The apparent peripheral pool carries free drug and is not a separately sampled serum compartment.
• CLRC=CL is fixed. Drug mass usesmg and target accounting usesnmol; they must not be added together.
• Antibody149kDareferenceisassumed; target40000ng/LpernM follows reported dual-unit baseline.
• Target-turnover half-time is not drug terminal half-life.